Primecap Management Co. CA Sells 65,100 Shares of Abbott Laboratories $ABT

Primecap Management Co. CA trimmed its holdings in shares of Abbott Laboratories (NYSE:ABT) by 7.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 810,390 shares of the healthcare product maker’s stock after selling 65,100 shares during the quarter. Primecap Management Co. CA’s holdings in Abbott Laboratories were worth $108,544,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in ABT. Vanguard Group Inc. lifted its holdings in Abbott Laboratories by 1.8% during the 2nd quarter. Vanguard Group Inc. now owns 172,800,851 shares of the healthcare product maker’s stock valued at $23,502,644,000 after buying an additional 2,977,715 shares in the last quarter. State Street Corp raised its position in Abbott Laboratories by 0.9% during the 2nd quarter. State Street Corp now owns 78,354,270 shares of the healthcare product maker’s stock valued at $10,656,964,000 after purchasing an additional 689,517 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Abbott Laboratories by 3.8% during the 2nd quarter. Geode Capital Management LLC now owns 38,293,067 shares of the healthcare product maker’s stock worth $5,184,589,000 after buying an additional 1,390,554 shares in the last quarter. Norges Bank purchased a new position in shares of Abbott Laboratories during the second quarter valued at $3,026,180,000. Finally, Massachusetts Financial Services Co. MA increased its stake in shares of Abbott Laboratories by 5.8% during the third quarter. Massachusetts Financial Services Co. MA now owns 15,096,907 shares of the healthcare product maker’s stock valued at $2,022,080,000 after buying an additional 821,325 shares during the period. 75.18% of the stock is currently owned by institutional investors.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Analyst/bullish research: A Seeking Alpha piece argues Abbott’s recent pullback is a buying opportunity, citing attractive profitable-growth characteristics and positioning for recovery. Abbott’s Meltdown Is Worth Buying
• Positive Sentiment: Income and steady growth pitch: The Motley Fool highlights Abbott as a steady income stock with double‑digit earnings growth and a dependable dividend, supporting longer-term total‑return appeal. Forget Tilray: This Steady Income Stock Beats Wild Cannabis Swings Every Time
• Neutral Sentiment: Valuation snapshot shows mixed signals: A Yahoo Finance valuation piece notes short‑term momentum has been weak and longer‑term returns negative, leaving conflicting “fair value” signals for investors to reconcile. Assessing Abbott Laboratories (ABT) Valuation
• Neutral Sentiment: Peer comparison: Coverage comparing Abbott to Intuitive Surgical frames Abbott as the steadier, dividend‑paying medtech pick, while Intuitive may offer higher growth from procedural/robotics expansion — useful for portfolio allocation but not an immediate earnings shock. Intuitive Surgical or Abbott: Which MedTech Stock Is a Better Bet Now?
• Neutral Sentiment: Sector noise from diagnostics peers: A large drop in Grail’s stock after trial updates is creating headline risk for diagnostics names; this may press sentiment in the broader diagnostics/medtech complex but does not directly change Abbott’s fundamentals. Grail’s Stock Dropped 50% on Friday
• Negative Sentiment: Underperformance and analyst skepticism: Multiple pieces note ABT has underperformed the Nasdaq and that some research houses have trimmed price targets and flagged execution/earnings-translation risk — pressure that can weigh on sentiment until clarity on growth drivers. Is Abbott Laboratories Stock Underperforming the Nasdaq?
• Negative Sentiment: Split analyst views driving volatility: A market narrative piece documents a wide range of recent price‑target moves (some cuts, at least one raise into the mid‑$150s), leaving investors with conflicting signals and more volatile price action. How The Evolving Wall Street Narrative Is Reframing Abbott Laboratories (ABT) Valuation Prospects

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on ABT shares. Argus dropped their target price on shares of Abbott Laboratories from $150.00 to $140.00 in a report on Tuesday, January 27th. Barclays lowered their price target on shares of Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating for the company in a research report on Monday, February 2nd. BTIG Research cut their price objective on shares of Abbott Laboratories from $145.00 to $140.00 and set a “buy” rating on the stock in a report on Tuesday, February 17th. Daiwa Securities Group reduced their price objective on shares of Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating for the company in a research note on Friday, January 30th. Finally, Royal Bank Of Canada dropped their target price on Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, Abbott Laboratories currently has an average rating of “Moderate Buy” and a consensus target price of $137.05.

Insider Activity

In related news, Director Daniel J. Starks acquired 10,000 shares of the business’s stock in a transaction dated Wednesday, February 4th. The shares were purchased at an average price of $108.73 per share, for a total transaction of $1,087,300.00. Following the completion of the acquisition, the director directly owned 6,738,817 shares in the company, valued at $732,711,572.41. The trade was a 0.15% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.46% of the stock is currently owned by company insiders.

Abbott Laboratories Price Performance

Shares of ABT opened at $116.21 on Friday. The company has a 50 day moving average of $117.53 and a two-hundred day moving average of $125.41. The company has a quick ratio of 1.24, a current ratio of 1.58 and a debt-to-equity ratio of 0.19. Abbott Laboratories has a twelve month low of $105.27 and a twelve month high of $141.23. The company has a market cap of $201.94 billion, a price-to-earnings ratio of 31.24, a price-to-earnings-growth ratio of 1.83 and a beta of 0.75.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting the consensus estimate of $1.50. The firm had revenue of $11.46 billion during the quarter, compared to analyst estimates of $11.80 billion. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The business’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a dividend of $0.63 per share. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.2%. Abbott Laboratories’s payout ratio is presently 67.74%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.